BR9811533A - Produção de compostos avermectina - Google Patents

Produção de compostos avermectina

Info

Publication number
BR9811533A
BR9811533A BR9811533-2A BR9811533A BR9811533A BR 9811533 A BR9811533 A BR 9811533A BR 9811533 A BR9811533 A BR 9811533A BR 9811533 A BR9811533 A BR 9811533A
Authority
BR
Brazil
Prior art keywords
compound
reacting
alkyl
formula
production
Prior art date
Application number
BR9811533-2A
Other languages
English (en)
Inventor
Masanori Honda
Hiroshi Kadoi
Hiromasa Morita
Isao Nagakura
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/IB1998/000988 external-priority patent/WO1999005156A1/en
Publication of BR9811533A publication Critical patent/BR9811533A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção: <B>"PRODUçãO DE COMPOSTOS AVERMECTINA"<D>. Esta invenção fornece um processo para preparar um composto de fórmula (I) em que R^ 1^ é H ou um grupo protetor de hidróxiimino; R^ 2^ é H, C~ 1-4~ alquila ou C~ 1-4~ alcóxi; R~ 3~ é C~ 1-8~ alquila, C~ 2-8~ alcenila ou C~ 3-8~ cicloalquila; e R^ 4^ é H, halo, C~ 1-4~ alquila ou C~ 1-4~ alcóxi, cujo processo compreende os passos de: (a) fazer reagir um derivado da avermectina B2 com um agente oxidante para formar um composto 5-oxo; (b) fazer reagir o composto 5-oxo com um composto de fórmula R^ 1^-O-NH~ 2~ em que R^ 1^ é H ou um grupo protetor de hidróxiimino, para formar um composto 5-imino; (c) fazer reagir o composto 5-imino com um agente de tionocarbonilação para formar um éster 4",23-bistionocarbonila; (d) fazer reagir o éster 4",23-bistionocarbonila com um agente de desoxigenação para formar um composto 4",23-didesóxi; e (e) fazer reagir o composto 4",23-didesoxila com um ácido para formar um composto de fórmula (I).
BR9811533-2A 1997-07-23 1998-06-25 Produção de compostos avermectina BR9811533A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9700917 1997-07-23
PCT/IB1998/000988 WO1999005156A1 (en) 1997-07-23 1998-06-25 Production of avermectin compounds

Publications (1)

Publication Number Publication Date
BR9811533A true BR9811533A (pt) 2000-08-29

Family

ID=11004592

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9811533-2A BR9811533A (pt) 1997-07-23 1998-06-25 Produção de compostos avermectina
BR9812095-6A BR9812095A (pt) 1997-07-23 1998-07-03 Compostos de indol como inibidores de cox-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9812095-6A BR9812095A (pt) 1997-07-23 1998-07-03 Compostos de indol como inibidores de cox-2

Country Status (19)

Country Link
US (1) US6300363B1 (pt)
EP (1) EP1001934B1 (pt)
JP (1) JP3267635B2 (pt)
AP (1) AP9801302A0 (pt)
AR (1) AR016523A1 (pt)
AT (1) ATE228503T1 (pt)
AU (1) AU8030598A (pt)
BR (2) BR9811533A (pt)
CA (1) CA2295063C (pt)
CO (1) CO4810382A1 (pt)
DE (1) DE69809758T2 (pt)
DK (1) DK1001934T3 (pt)
ES (1) ES2184280T3 (pt)
HR (1) HRP980411A2 (pt)
MA (1) MA26526A1 (pt)
PA (1) PA8456101A1 (pt)
PT (1) PT1001934E (pt)
TN (1) TNSN98140A1 (pt)
WO (1) WO1999005104A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
FR2774097B1 (fr) * 1998-01-28 2000-09-29 Bio Merieux Utilisation de derives d'indolamine dans la detection d'une activite de peptidase ou dans la detection de micro-organismes
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE60000556T2 (de) * 1999-07-02 2003-02-13 Pfizer Inc., New York Tetrazolylalkyl-Indolderivate als entzündungshemmende und analgetische Mittel
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
NZ522246A (en) * 2000-04-28 2006-01-27 Baxter Healthcare Sa 2-acyl indole derivatives and their use as antitumor agents
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10152306A1 (de) * 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
ES2338539T3 (es) * 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
US7482488B2 (en) * 2002-08-29 2009-01-27 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
CA2519189C (en) 2003-05-07 2012-07-17 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
EP1646624A1 (en) * 2003-07-09 2006-04-19 Biolipox AB Indoles useful in the treatment of inflammation
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
MXPA06012510A (es) * 2004-04-28 2006-12-15 Pfizer Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
ES2315877T3 (es) 2004-06-18 2009-04-01 Biolipox Ab Indoles utiles en el tratamiento de inflamaciones.
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EA200701504A1 (ru) 2005-01-19 2008-02-28 Биолипокс Аб Индолы, пригодные для лечения воспалений
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
RS51940B (en) 2006-12-22 2012-02-29 Recordati Ireland Limited Combined TH2δ LIGANAD THERAPY AND NSAID FOR LOWER URINARY TRACT DISORDERS
EP2282735B1 (en) 2008-04-21 2019-01-16 Signum Biosciences, Inc. Pp2a modulators for treating alzheimer, parkinson, diabetes
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827326B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
US9808443B1 (en) 2016-11-28 2017-11-07 King Saud University Cyclooxygenase inhibitors
AU2019295765B2 (en) 2018-06-27 2024-08-29 Yumanity, Inc. Proteasome activity enhancing compounds
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013767A1 (de) 1995-10-09 1997-04-17 Chemisch Pharmazeutische Forschungsgesellschaft Mbh Heterocyclisch substituierte 1-indolcarboxamide als cyclooxygenase-2 inhibitoren
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents

Also Published As

Publication number Publication date
JP3267635B2 (ja) 2002-03-18
ES2184280T3 (es) 2003-04-01
CA2295063A1 (en) 1999-02-04
EP1001934B1 (en) 2002-11-27
MA26526A1 (fr) 2004-12-20
JP2000513386A (ja) 2000-10-10
PT1001934E (pt) 2003-02-28
EP1001934A1 (en) 2000-05-24
DE69809758D1 (de) 2003-01-09
TNSN98140A1 (fr) 2005-03-15
BR9812095A (pt) 2000-07-18
AR016523A1 (es) 2001-07-25
AU8030598A (en) 1999-02-16
US6300363B1 (en) 2001-10-09
PA8456101A1 (es) 2000-05-24
DE69809758T2 (de) 2003-04-10
HRP980411A2 (en) 1999-04-30
ATE228503T1 (de) 2002-12-15
CO4810382A1 (es) 1999-06-30
CA2295063C (en) 2005-10-18
AP9801302A0 (en) 2000-01-23
DK1001934T3 (da) 2002-12-30
WO1999005104A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
BR9811533A (pt) Produção de compostos avermectina
BR0212185A (pt) Compostos e métodos para a preparação de compostos
BR0014060A (pt) Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica
BR9401482A (pt) 1H-Indol-3-acetamida, formulação farmacêutica, utilização de um composto e processo para a preparação de 1h-indol-3-acetamida
MX9207152A (es) Composiciones farmaceuticas estabilizadas que comprenden un compuesto inhibidor de la hmg-coa reductasa y metodo para su preparacion.
ES2162165T3 (es) Procedimiento para la fabricacion de simvastatina o acido mevinolinico.
BR0208992A (pt) Processo para a preparação de indenos 1,3-substituìdos e compostos azapolicìclicos fundidos com arila
BR9909468A (pt) Composto anti-bacteriano, composição oral anti-placas, e, processo para promoção da higiene oral
ES2173179T3 (es) Procedimiento para preparar composiciones de avermectina/ceina.
BR0014461A (pt) Composto e método para preparar o mesmo
ES2155991T3 (es) Nuevos compuestos de terfenilo y medicamentos que contienen estos compuestos.
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
BR0103072A (pt) Processo para a preparação de compostos de pirazolo[4,3-d] pirimidin-7-ona e seus intermediários
BR0007982A (pt) Processo para a preparação de um composto, e,composto
PT1102765E (pt) Processo para a sintese de derivados de (1h)-benzo¬c|quinolizin-3-onas
BR0209284A (pt) Processo para preparação do fungicida agrìcola, azoxistrobina, e análogos do mesmo
BR0115872A (pt) Processo e derivados de éster úteis para a preparação de cefalosporinas
BR0009453A (pt) Processo para a preparação de um composto
BR9800565A (pt) Processo para a produção de compostos de halogeno-o-hidroxideifenila
AR016522A1 (es) Produccion de compuestos de avermectina
BR0114258A (pt) Esteróides de 17alfa-fluoroalquila, processo para sua produção e composições farmacêuticas que contêm estes compostos
BR0010112A (pt) Processo para preparação de ácido alendrÈnico
BR9906803A (pt) Processo para tratamento de copd
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
DE69809888D1 (de) Verfahren zur Herstellung von alpha-Aminoketonen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1994 DE 24/03/2009